- Home
- / Sunesis Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Sunesis Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
$120 K
FY, 2020
CreditSafe Score
?
Score changed on Jan 21, 2025
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.0M | 3.8M | 8.0M | 5.7M | 3.1M | 2.5M | 669.0K | 237.0K | 2.1M | 120.0K | |
| General and administrative expense | 8.3M | 9.2M | 10.8M | 23.1M | 18.7M | 16.1M | 13.5M | 11.3M | 9.9M | 10.2M | 15.4M |
| Operating expense total | 30.9M | 38.4M | 39.7M | 50.8M | 42.4M | 39.0M | 35.1M | 25.9M | 25.4M | 22.4M | |
| EBIT | (25.9M) | (34.6M) | (31.8M) | (45.0M) | (39.3M) | (36.5M) | (34.4M) | (25.7M) | (23.3M) | (22.3M) | (114.3M) |
| EBIT margin, % | -517.3% | -921.8% | -399.4% | -785.5% | -1284.0% | -1437.7% | -5144.8% | -10848.1% | -1123.4% | -18585.8% | |
| Interest income | 38.0K | ||||||||||
| Interest expense | 109.0K | 1.9M | |||||||||
| Pre tax profit | (34.6M) | (43.0M) | (36.7M) | (38.0M) | (35.5M) | (26.6M) | (23.3M) | (21.6M) | |||
| Net Income | (20.1M) | (44.0M) | (34.6M) | (43.0M) | (36.7M) | (38.0M) | (35.5M) | (26.6M) | (23.3M) | (21.6M) | (114.8M) |